Federal Court in California Orders GSK CEO To Answer Questions in AIDS Healthcare Foundation Lawsuit on AZT Patent

Main Category: Pharma Industry / Biotech Industry
Article Date: 06 Apr 2005 - 11:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


US District Court Magistrate Judge Charles Eick in California has ruled that GlaxoSmithKline CEO Jean-Pierre Garnier must answer additional questions in the lawsuit brought against the company by the... AIDS Healthcare Foundation, which seeks to block the company's patent for its antiretroviral drug Retrovir, more commonly known as AZT or zidovudine, AFX News reports (AFX News, 4/4). AHF, the largest nongovernmental provider of health care services for people with HIV/AIDS in the United States, in April 2003 filed an amended lawsuit in federal court against GSK, challenging the company's patents for three of its top-selling antiretroviral drugs. AHF's original suit, which was dismissed in March 2003, charged that several of GSK's patents for its antiretroviral drugs are invalid and that its prices "exorbitantly exceed" its licensing, manufacturing and distribution costs. In the new suit, AHF says that NIH, with federal funding, developed Retrovir in 1964 as a cancer drug and that NIH scientists tested the drug as an HIV medication 17 months before GSK filed its patent in the mid-1980s. Under U.S. law, drugs developed with federal funds must be sold at a reasonable price that could, if necessary, be determined by the courts. AHF alleges that the patent on Retrovir locked out competitors and allowed the company to price the drug at 32 times its manufacturing cost. Because Retrovir was developed with federal funding, the drug and subsequent derivative drugs -- such as the combination drugs Combivir and Trizivir, which include Retrovir -- should be sold at more reasonable rates, according to the suit (Kaiser Daily HIV/AIDS Report, 7/29/03). Garnier answered questions in a deposition with AHF lawyers in January, but AHF attorneys said that he "left some questions unanswered," according to AFX News. Eick ruled that AHF could continue Garnier's deposition (AFX News, 4/4).

"Reprinted with permission from kaisernetwork.org kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv.. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Combivir; Trizivir.


Article adapted by Medical News Today from original press release.
Visit our pharma industry / biotech industry section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Mary Sweeney. "Federal Court in California Orders GSK CEO To Answer Questions in AIDS Healthcare Foundation Lawsuit on AZT Patent." Medical News Today. MediLexicon, Intl., 6 Apr. 2005. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/22383.php>

APA
Mary Sweeney. (2005, April 6). "Federal Court in California Orders GSK CEO To Answer Questions in AIDS Healthcare Foundation Lawsuit on AZT Patent." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/22383.php.

Please note: If no author information is provided, the source is cited instead.


Pharma Industry / Biotech Industry

Most Popular Articles



Follow Our Pharma Industry News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pharma Industry / Biotech Industry Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »